US stocks look set to open marginally lower in Thursday's trading session as investors parse relatively bullish economic data that came out earlier this morning, including Q1 GDP growth, weekly jobless claims, and durable goods orders for May.
The Dow Jones Industrial Average futures were down 0.22%, S&P 500 futures were off 0.04%, and Nasdaq futures were moving 0.10% lower.
Oil prices were moving higher, with front-month global benchmarks Brent crude up 0.92% and West Texas Intermediate crude rising 0.82%
The Bureau of Economic Analysis' third estimate for Q1 GDP indicated an annual growth rate of 1.4%, up from its previous estimate of 1.3%, in line with the 1.4% increase expected in a survey compiled by Bloomberg as of 7:50 am ET.
Weekly jobless claims declined more than expected to 233,000 in the week ended June 22 from 239,000 the previous week. The consensus forecast was for a smaller decrease to 235,000 in a survey compiled by Bloomberg as of 7:50 am ET.
And durable goods orders in May rose 0.1%, after increasing 0.2% the previous month, and topping analyst expectations of a 0.5% decline.
In other world markets, Japan's Nikkei dropped 0.82%, Hong Kong's Hang Seng plunged 2.06%, and China's Shanghai Composite was down 0.90%. Meanwhile in Europe's early afternoon session, the UK's FTSE 100 was off 0.12%, while Germany's DAX was up 0.12% and France's CAC was down 0.75%.
On the winning side, shares of Assure (IONM) soared 154% in Thursday's premarket session after gaining nearly 3% the previous session. NLS Pharmaceutics' (NLSP) stock shot up 110% after it reported Thursday preclinical results from multiple studies that demonstrate the potential to advance the treatment of Parkinson's Disease. SinglePoint (SING) shares jumped 79%, adding to 42% gain Wednesday. CASI Pharmaceuticals' (CASI) shares climbed 34% after it said late Wednesday that it will submit an investigational new-drug application to the US Food and Drug Administration by the end of the year for CID-103 to treat antibody-mediated rejection in kidney transplant patients. And shares of Vigil Neuroscience (VIGL) advanced 22% after it said Thursday that Sanofi (SNY) has made a $40 million strategic investment in the company at an as-converted price of $7.44 per share of common stock.
On the losing side, shares of Tonix Pharmaceuticals (TNXP) plunged 44% after it said late Wednesday that it plans to offer and sell shares of its common stock or pre-funded warrants. BranchOut Food (BOF) shed 40% after it said late Wednesday that it priced an underwritten public offering of its about 1.8 million common shares at $0.80 each. Immutep's (IMMP) stock dropped 32% after analysts at Baird lowered their price target on the stock to $6 From $7. Shares of Bluejay Diagnostics (BJDX) tumbled 46%, adding to Wednesday's 41% loss. And Recursion Pharmaceuticals' (RXRX) shares fell 20% after it said late Wednesday it priced a public offering of 30.8 million shares of its class A common stock at $6.50 each.
Comments